Biologica in patients with ulcerative colitis in Germany (BioColitis study)
- Conditions
- K51Ulcerative colitis
- Registration Number
- DRKS00009219
- Lead Sponsor
- CED Service GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 885
Inclusion Criteria
1. ulcerative colitis patients (age at inclusion: 18-80 years ) with a new biologics therapy with Adalimumab, Infliximab, Golimumab or Vedolizumab.
2. ulcerative colitis patients (age at inclusion: 18-80 years ) with an early disease history (initial diagnosis <2 years).
Exclusion Criteria
Age < 18 years >80 years
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method